First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6–Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non–Small Cell Lung Cancer

Solange Peters, Sarina A. Piha-Paul, Kartik Sehgal, Emiliano Calvo, Bruno Bockorny, Vladimir Galvao, Afshin Dowlati, Elisa Fontana, Tatiana Hernandez-Guerrero, Fernando Rivera Herrero, Edwin Kingsley, Juanita S. Lopez, Amita Patnaik, Cesar Augusto Perez, Rachel E. Sanborn, Scott Knowles, Gabriela Patilea-Vrana, Jerry Li, Tianhua Wang, Yimo Wang, Antoine Hollebecque

Open source

DOI: 10.1200/jco-25-02016
Published: 2026-06-10
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-25-02016,
  title = {First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6–Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non–Small Cell Lung Cancer},
  author = {Solange Peters and Sarina A. Piha-Paul and Kartik Sehgal and Emiliano Calvo and Bruno Bockorny and Vladimir Galvao and Afshin Dowlati and Elisa Fontana and Tatiana Hernandez-Guerrero and Fernando Rivera Herrero and Edwin Kingsley and Juanita S. Lopez and Amita Patnaik and Cesar Augusto Perez and Rachel E. Sanborn and Scott Knowles and Gabriela Patilea-Vrana and Jerry Li and Tianhua Wang and Yimo Wang and Antoine Hollebecque},
  year = {2026},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco-25-02016},
  url = {https://doi.org/10.1200/jco-25-02016}
}

RIS

TY  - JOUR
TI  - First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6–Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non–Small Cell Lung Cancer
AU  - Solange Peters
AU  - Sarina A. Piha-Paul
AU  - Kartik Sehgal
AU  - Emiliano Calvo
AU  - Bruno Bockorny
AU  - Vladimir Galvao
AU  - Afshin Dowlati
AU  - Elisa Fontana
AU  - Tatiana Hernandez-Guerrero
AU  - Fernando Rivera Herrero
AU  - Edwin Kingsley
AU  - Juanita S. Lopez
AU  - Amita Patnaik
AU  - Cesar Augusto Perez
AU  - Rachel E. Sanborn
AU  - Scott Knowles
AU  - Gabriela Patilea-Vrana
AU  - Jerry Li
AU  - Tianhua Wang
AU  - Yimo Wang
AU  - Antoine Hollebecque
PY  - 2026
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco-25-02016
UR  - https://doi.org/10.1200/jco-25-02016
ER  -

APA

Peters, S., Piha-Paul, S. A., Sehgal, K., Calvo, E., Bockorny, B., Galvao, V., Dowlati, A., Fontana, E., Hernandez-Guerrero, T., Herrero, F. R., Kingsley, E., Lopez, J. S., Patnaik, A., Perez, C. A., Sanborn, R. E., Knowles, S., Patilea-Vrana, G., Li, J., Wang, T., Wang, Y., & Hollebecque, A. (2026). First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6–Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non–Small Cell Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-02016

Source records

crossref · retrieved 2026-09-26T10:05:05.708Z